What Gamma Biosciences does

Gamma Biosciences is a private bioprocessing holding company founded in 2019 and headquartered in Menlo Park, California, that builds a portfolio of products and services for advanced biologic therapies, with a focus on cell and gene therapy and next-generation vaccine manufacturers. The company operates through a multi-subsidiary platform that covers adjacent stages of the bioprocessing workflow, including Astrea Bioseparations (bioseparation products, including the Nereus LentiHERO fit-for-purpose lentiviral vector purification solution), Nanopareil (next-generation purification technology), and BioMagnetic Solutions (magnetic-based bioprocessing solutions operating an ISO-certified GMP facility at Penn State's Innovation Park). Through Mirus Bio (acquired in 2021 and subsequently divested to Merck Group in August 2024), Gamma had exposure to viral vector bioprocessing and to lipid-polymer nanocomplex development for in vivo mRNA delivery, and a related mRNA delivery initiative was launched in January 2025.

The company's underlying technology stack is built around purification, separation, and delivery chemistries for complex biologics rather than around software or data platforms. Recent product and infrastructure moves — including the Nereus LentiHERO launch in September 2025 and the BioMagnetic Solutions GMP buildout in November 2025 — extend the platform from upstream purification IP into GMP-compliant manufacturing capacity for biopharma customers.

Gamma Biosciences makes money through B2B product sales and services to biopharmaceutical customers, primarily via enterprise field sales targeting gene therapy developers and vaccine manufacturers. The company has raised $200 million in funding from Kohlberg Kravis Roberts (KKR) and Univercells (round dated February 2020), and revenue is not publicly disclosed. The acquisition-heavy growth model — Nanopareil (2020), BioMagnetic Solutions (2021), Mirus Bio (2021), and the Mirus Bio divestiture to Merck (2024) — combined with new product launches and a GMP buildout, point to a roll-up strategy designed to assemble a vertically integrated bioprocessing platform serving the cell and gene therapy value chain.

Name

Gamma Biosciences

Legal name

Gamma Biosciences

Website

https://gammabiosciences.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Gamma Biosciences is a private, Menlo Park-based bioprocessing holding company that builds purification, viral vector, mRNA delivery, and GMP manufacturing technologies for cell and gene therapy and vaccine developers through subsidiaries including Astrea Bioseparations, Nanopareil, and BioMagnetic Solutions.

Ownership category

akta.pro rank

Product category

Bioprocessing Equipment and Consumables

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Analytical Laboratory Instrument Manufacturing (334516), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD)

akta.pro secondary industries

Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

Keywords

• Bioprocessing technologies
• Cell and gene therapy
• Viral vector purification
• Biologic therapy manufacturing
• Bioseparation products

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Bioprocessing Products and Services: Develops and sells products and services to support biologic therapies, including viral vector purification solutions, mRNA delivery systems, and related bioprocessing technologies. Revenue is generated through product sales to life sciences and biopharma customers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Gamma Biosciences is a life sciences platform company that develops and supplies bioprocessing products and services to support the manufacturing of biologic therapies, including gene therapies and next-generation vaccines. Its portfolio spans viral vector purification technologies, mRNA delivery systems, bioseparation chromatography products, and GMP-grade manufacturing services delivered through operating subsidiaries such as Astrea Bioseparations, Mirus Bio, Nanopareil, and BioMagnetic Solutions.

Product overview

Gamma Biosciences is a life sciences company founded in 2019 and based in Menlo Park, California, that develops products and services to support biologic therapies. The company operates as a platform of subsidiaries and acquired companies in the bioprocessing industry, with a portfolio that includes Astrea Bioseparations (bioseparation products), Mirus Bio (gene therapy and vaccine technologies), Nanopareil (purification capabilities), and BioMagnetic Solutions (magnetic-based solutions). The company has raised $200 million in funding and serves the cell and gene therapy sector with a focus on manufacturing scalability, viral vector bioprocessing, and purification solutions.

Differentiator

Problem solved

Functional benefit

Brands

• Nereus LentiHERO: Fit-for-purpose solution for lentiviral vector purification developed by Astrea Bioseparations

Products and services

• Nereus LentiHERO A fit-for-purpose purification solution developed by Astrea Bioseparations for lentiviral vector purification, supporting cell and gene therapy manufacturing workflows. Intended for biopharmaceutical manufacturers developing gene therapies.
• Astrea Bioseparations Bioseparation Products Bioseparation chromatography products and services supporting biologic therapy manufacturing, including lentiviral vector purification solutions for gene therapy developers.
• Mirus Bio Gene Therapy and Vaccine Products Products and technologies for gene therapy and next-generation vaccine development, including lipid-polymer nanocomplexes for in vivo mRNA delivery. Sold to biopharma companies developing cell and gene therapies and vaccines.
• Nanopareil Next-Generation Purification Products Next-generation purification technologies integrated into Astrea Bioseparations' portfolio, supporting advanced therapy bioprocessing.
• BioMagnetic Solutions Magnetic-Based Bioprocessing Products and GMP Manufacturing Magnetic-based bioprocessing solutions and ISO-certified GMP manufacturing services provided from the Penn State Innovation Park facility, available to biopharmaceutical customers.

Quantifiable outcome

• Acquisition of Nanopareil advances next-generation purification capabilities
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Penn State Innovation ParkcoreStrategic or Co-development Partner · 16 November 2025BioMagnetic Solutions, a Gamma Biosciences subsidiary, confirmed ISO certifications and GMP facility build at Innovation Park at Penn State. This partnership provides manufacturing infrastructure for bioprocessing operations.
• Merck GroupminorOthers · 1 August 2024Merck Group closed acquisition of Mirus Bio, which was previously a Gamma Biosciences subsidiary. This represents a divestiture rather than a partnership.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Cytiva: Bioprocessing giant (Danaher subsidiary) supplying filtration, chromatography, and single-use systems for biologics and viral vector manufacturing. Overlaps directly with Gamma's Astrea Bioseparations and lentiviral purification portfolio.
• Sartorius: Global bioprocessing supplier of upstream/downstream equipment and consumables for cell and gene therapy production. Competes with Gamma across viral vector purification and bioprocess tools.
• Merck KGaA (Life Science / MilliporeSigma): Bioprocessing incumbent that acquired Mirus Bio from Gamma in 2024. Now a direct competitor in viral vector bioprocessing and mRNA delivery, and validates Gamma's prior Mirus Bio thesis.
• Thermo Fisher Scientific: Diversified life sciences giant with viral vector services (Brammer Bio) and bioproduction capabilities. Competes across the full cell and gene therapy bioprocessing value chain.
• Avantor: Supplier of bioprocessing inputs, single-use solutions, and laboratory products serving biopharma manufacturers. Overlaps with Gamma's consumables and bioprocessing product portfolio.

Direct peers

• Repligen: Pure-play bioprocessing tools company specializing in chromatography, filtration, and process analytics. Directly comparable to Astrea Bioseparations in bioseparation consumables.
• Lonza: Leading CDMO with significant cell and gene therapy manufacturing services and bioprocess tools. Comparable business model combining GMP services with proprietary bioprocessing technology.
• AGC Biologics: CDMO offering viral vector and cell therapy manufacturing services with proprietary process platforms. Closely aligned with Gamma's gene therapy manufacturing focus.

Emerging players

• Bio-Techne: Life sciences reagent and bioprocessing consumables supplier expanding into cell and gene therapy workflow tools. Emerging competitor in purification and process analytics.

Regional players

• WuXi Advanced Therapies: Cell and gene therapy CDMO with substantial viral vector manufacturing capacity. Operates primarily in Asia-Pacific but serves global biopharma, comparable in scale and capability.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/BioGamma

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gamma Biosciences